Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
- PMID: 15289815
- DOI: 10.1038/sj.mp.4001556
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
Abstract
The treatment of schizophrenia has evolved over the past half century primarily in the context of antipsychotic drug development. Although there has been significant progress resulting in the availability and use of numerous medications, these reflect three basic classes of medications (conventional (typical), atypical and dopamine partial agonist antipsychotics) all of which, despite working by varying mechanisms of actions, act principally on dopamine systems. Many of the second-generation (atypical and dopamine partial agonist) antipsychotics are believed to offer advantages over first-generation agents in the treatment for schizophrenia. However, the pharmacological properties that confer the different therapeutic effects of the new generation of antipsychotic drugs have remained elusive, and certain side effects can still impact patient health and quality of life. Moreover, the efficacy of antipsychotic drugs is limited prompting the clinical use of adjunctive pharmacy to augment the effects of treatment. In addition, the search for novel and nondopaminergic antipsychotic drugs has not been successful to date, though numerous development strategies continue to be pursued, guided by various pathophysiologic hypotheses. This article provides a brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotics, and focuses on novel targets for therapeutic agents for future drug development.
Similar articles
-
Schizophrenia treatment. Critical review on the drugs and mechanisms of action of antipsychotics.Actas Esp Psiquiatr. 2009 Nov-Dec;37(6):330-42. Actas Esp Psiquiatr. 2009. Retraction in: Actas Esp Psiquiatr. 2012 Mar-Apr;40(2):104. PMID: 20066585 Retracted. Review.
-
[Critical review of mechanisms of action of second-generation antipsychotic drugs].Nihon Shinkei Seishin Yakurigaku Zasshi. 2006 Nov;26(5-6):199-208. Nihon Shinkei Seishin Yakurigaku Zasshi. 2006. PMID: 17240845 Review. Japanese.
-
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Mol Psychiatry. 2012 Dec;17(12):1206-27. doi: 10.1038/mp.2012.47. Epub 2012 May 15. Mol Psychiatry. 2012. PMID: 22584864 Review.
-
Evolution of schizophrenia drugs: a focus on dopaminergic systems.Curr Opin Investig Drugs. 2008 Jan;9(1):37-46. Curr Opin Investig Drugs. 2008. PMID: 18183530 Review.
-
Receptor mechanisms in the treatment of schizophrenia.J Psychopharmacol. 2004 Sep;18(3):340-5. doi: 10.1177/026988110401800303. J Psychopharmacol. 2004. PMID: 15358977 Review.
Cited by
-
Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jul 3;60:66-76. doi: 10.1016/j.pnpbp.2015.02.012. Epub 2015 Feb 24. Prog Neuropsychopharmacol Biol Psychiatry. 2015. PMID: 25724760 Free PMC article. Review.
-
Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice.Psychopharmacology (Berl). 2013 Jan;225(1):217-26. doi: 10.1007/s00213-012-2809-7. Epub 2012 Jul 28. Psychopharmacology (Berl). 2013. PMID: 22842765 Free PMC article.
-
Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.Front Neurol. 2015 Feb 20;6:27. doi: 10.3389/fneur.2015.00027. eCollection 2015. Front Neurol. 2015. PMID: 25750634 Free PMC article. Review.
-
In vivo neurometabolic profiling to characterize the effects of social isolation and ketamine-induced NMDA antagonism: a rodent study at 7.0 T.Schizophr Bull. 2014 May;40(3):566-74. doi: 10.1093/schbul/sbt067. Epub 2013 May 13. Schizophr Bull. 2014. PMID: 23671195 Free PMC article.
-
Priapism in antipsychotic drug use: a rare but important side effect.Case Rep Psychiatry. 2012;2012:496364. doi: 10.1155/2012/496364. Epub 2012 Jun 5. Case Rep Psychiatry. 2012. PMID: 22934218 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
